KEI December 2, 2016 meeting on the delinkage of R&D costs from drug prices

KEI is holding a December 2, 2016 meeting on the delinkage of R&D costs from drug prices.

The venue will be US Senate Hearing Room SD-106, Dirksen Office Building. The meeting will take place from 9:00am to 2:00pm.

A copy of the agenda is available here.

For more information about delinkage, see: http://delinkage.org.

To register for the event, please fill out this form: https://goo.gl/forms/AbP2npqLRLYneLjk1.

For more information about the event, contact claire.cassedy@keionline.org.

The topics discussed at the meeting will include:

  • What is delinkage, and why is it important?
  • Reform of pull mechanisms
  • What are end product prizes, and how do they work?
  • What is the open source dividend, how does it work, and why is it important?
  • How interim results prizes work
  • Making global norms for R&D funding (both push and pull)
  • Strategies for progressive delinkage
  • Next steps

Attached is the most recent agenda (as updates are released, we will update the agenda below). Speakers and respondents include:

  • Aidan Hollis, Professor, Department of Economics, University of Calgary
  • Dean Baker, co-Director of the Center for Economic and Policy Research
  • Diane Singhroy, Scientific Advisor, Knowledge Ecology International
  • Ellen ‘t Hoen, LLM. Medicines Law & Policy and Global Health Unit, University Medical Center Groningen, University of Groningen, The Netherlands.
  • James Love, Knowledge Ecology International (KEI)
  • James L. McGee, CEBS, Executive Director, Transit Employees’ Health & Welfare Fund
  • Joe Larsen, Ph.D., Deputy Director (acting), Biomedical Advanced Research Development Authority (BARDA)
  • John Wilbanks, Chief Commons Officer at Sage Bionetworks and a Senior Fellow at the Ewing Marion Kauffman Foundation and at FasterCures
  • Judit Rius, Médecins sans frontières
  • Katy Athersuch, Medical Innovation & Access Policy Adviser
  • Manon Ress, Union for Affordable Cancer Treatment (UACT)
  • Patrick Kilbride, Executive Director, International Intellectual Property, GIPC at U.S. Chamber of Commerce
  • Rachel Cohen, DNDi
  • Rishab Ghosh, Maastricht University
  • Rob Weissman, President, Public Citizen
  • Sakiko Fukuda-Parr. Professor of International Affairs, The New School in New York, member of the UN Secretary General High Level Panel on Access to Medicine.
  • Tim Hubbard, Professor of Bioinformatics, King’s College London